{"id":"nucleoside-analogs","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":{"chemblId":"CHEMBL410780","moleculeType":"Protein","molecularWeight":"2685.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nucleoside analogs are incorporated into viral or cellular DNA/RNA during replication, causing chain termination or introducing mutations that prevent proper nucleic acid function. They are used broadly across antiviral and anticancer therapies, with specific mechanisms depending on the particular analog and target pathogen or malignancy.","oneSentence":"Nucleoside analogs are synthetic molecules that mimic natural nucleosides and inhibit viral or cancer cell replication by interfering with nucleic acid synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:50.991Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Viral infections (HIV, hepatitis B, herpes simplex, cytomegalovirus)"},{"name":"Hematologic malignancies and solid tumors"}]},"trialDetails":[{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT01581554","phase":"","title":"Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-05-18","conditions":"Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative","enrollment":15},{"nctId":"NCT07283900","phase":"PHASE2","title":"Ascorbate in Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Prajwal Dhakal","startDate":"2026-03-11","conditions":"Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT03366116","phase":"PHASE1","title":"5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-11-05","conditions":"Neoplasms, Solid Tumors","enrollment":65},{"nctId":"NCT02423057","phase":"PHASE1","title":"Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-05-18","conditions":"Neoplasms, Solid Tumors","enrollment":27},{"nctId":"NCT07060001","phase":"PHASE2","title":"Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)","enrollment":112},{"nctId":"NCT07341386","phase":"PHASE4","title":"Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-04-01","conditions":"Autoimmune Rheumatic Diseases, Recurrent Herpes Simplex, Prevention","enrollment":62},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT02425904","phase":"PHASE2","title":"Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-05","conditions":"Langerhans Cell Histiocytosis","enrollment":25},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT04375800","phase":"PHASE2","title":"Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-03","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":84},{"nctId":"NCT04496882","phase":"PHASE4","title":"Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-09-09","conditions":"Chronic Hepatitis b, Hepatitis B Reactivation","enrollment":260},{"nctId":"NCT04223778","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":672},{"nctId":"NCT07404332","phase":"PHASE1","title":"5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mohammed Milhem","startDate":"2026-02-28","conditions":"Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor","enrollment":35},{"nctId":"NCT04431245","phase":"","title":"Stopping Antiviral Treatment in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-06-01","conditions":"Chronic Hepatitis b","enrollment":54},{"nctId":"NCT07148180","phase":"PHASE1, PHASE2","title":"A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax","status":"RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2026-02-02","conditions":"Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer","enrollment":31},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT07372352","phase":"PHASE2","title":"Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-15","conditions":"Peripheral T Cells Lymphoma (PTCL)","enrollment":26},{"nctId":"NCT06644417","phase":"PHASE2","title":"Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-14","conditions":"HBV Infection With LLV","enrollment":122},{"nctId":"NCT07366840","phase":"PHASE2, PHASE3","title":"RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-16","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer","enrollment":268},{"nctId":"NCT06429449","phase":"PHASE1","title":"Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-07-21","conditions":"Leukemia, Myeloid Leukemia, Monocytic Leukemia","enrollment":30},{"nctId":"NCT04891068","phase":"PHASE2","title":"BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2022-01-10","conditions":"Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":40},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT04881240","phase":"PHASE1","title":"Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-02-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL","enrollment":60},{"nctId":"NCT06232655","phase":"PHASE2","title":"Cladribine Venetoclax in Monocytic AML","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-02-08","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06856837","phase":"PHASE2","title":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-10-27","conditions":"Metastatic Colorectal Cancer","enrollment":140},{"nctId":"NCT06783140","phase":"PHASE2, PHASE3","title":"Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-06-10","conditions":"Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation","enrollment":10},{"nctId":"NCT03342196","phase":"PHASE2","title":"Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2018-03-21","conditions":"Leukemia","enrollment":40},{"nctId":"NCT07257562","phase":"","title":"Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2025-06-01","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT07252869","phase":"","title":"Evaluation of Impression Accuracy: Digital Scanner Versus Analog Technique","status":"COMPLETED","sponsor":"University of Milan","startDate":"2017-07-15","conditions":"Accuracy and Precision of Noninvasive Measurement","enrollment":51},{"nctId":"NCT06706310","phase":"PHASE2","title":"Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-12-04","conditions":"Chronic Hepatitis B","enrollment":116},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)","enrollment":67},{"nctId":"NCT05325281","phase":"PHASE1","title":"CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2022-10-31","conditions":"Pancreas Adenocarcinoma","enrollment":8},{"nctId":"NCT04937166","phase":"PHASE1","title":"A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies","status":"TERMINATED","sponsor":"Kahr Medical","startDate":"2022-01-13","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia","enrollment":25},{"nctId":"NCT04897321","phase":"PHASE1","title":"B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-07-06","conditions":"Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma","enrollment":32},{"nctId":"NCT04318678","phase":"PHASE1","title":"CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-07-29","conditions":"AML/MDS, B-ALL, T-ALL","enrollment":108},{"nctId":"NCT03365947","phase":"PHASE1, PHASE2","title":"Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2018-03-27","conditions":"Hepatitis B","enrollment":114},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT06102525","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma","status":"RECRUITING","sponsor":"Rznomics, Inc.","startDate":"2024-10-08","conditions":"Glioblastoma","enrollment":43},{"nctId":"NCT01309490","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients","status":"TERMINATED","sponsor":"Jewish General Hospital","startDate":"2011-03-17","conditions":"Malignant Solid Tumor","enrollment":5},{"nctId":"NCT04102176","phase":"NA","title":"Halting Nucleoside Analogues in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seng Gee Lim","startDate":"2019-01-29","conditions":"Chronic Hepatitis B","enrollment":120},{"nctId":"NCT07031063","phase":"PHASE4","title":"Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-04-01","conditions":"HIV Infection, Metabolic Syndrome, Antiretroviral Treatment","enrollment":124},{"nctId":"NCT05451043","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-07-05","conditions":"Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer","enrollment":62},{"nctId":"NCT01059786","phase":"PHASE2","title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-01","conditions":"Hairy Cell Leukemia","enrollment":69},{"nctId":"NCT07011186","phase":"PHASE1, PHASE2","title":"A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-04-17","conditions":"Myeloid Malignancy","enrollment":138},{"nctId":"NCT00796263","phase":"PHASE3","title":"Antiretroviral Therapy for Acute and Chronic HIV Infection","status":"RECRUITING","sponsor":"SEARCH Research Foundation","startDate":"2009-05-13","conditions":"Acute HIV Infection, Chronic HIV Infection","enrollment":900},{"nctId":"NCT03066648","phase":"PHASE1","title":"Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-07-06","conditions":"Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute","enrollment":241},{"nctId":"NCT03304717","phase":"PHASE1, PHASE2","title":"Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome","status":"WITHDRAWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-12","conditions":"Aicardi Goutières Syndrome","enrollment":""},{"nctId":"NCT05182463","phase":"PHASE4","title":"Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-01-08","conditions":"Hepatitis B, Chronic","enrollment":5000},{"nctId":"NCT05328427","phase":"NA","title":"Discontinuation of Antiviral Therapy as a Strategy to Cure Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-11-01","conditions":"Hepatitis B, Chronic","enrollment":33},{"nctId":"NCT04035837","phase":"PHASE4","title":"The Clinical Cure Project of Chronic Hepatitis B in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-05-16","conditions":"Hepatitis B, Chronic","enrollment":30000},{"nctId":"NCT03257267","phase":"PHASE3","title":"Study of Cemiplimab in Adults With Cervical Cancer","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-09-05","conditions":"Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer","enrollment":608},{"nctId":"NCT00866021","phase":"PHASE4","title":"Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-02","conditions":"HIV/HCV Co-infection, HIV Infections","enrollment":68},{"nctId":"NCT04885855","phase":"PHASE2, PHASE3","title":"8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Muhammad Radzi Abu Hassan","startDate":"2021-03-23","conditions":"Hepatitis C","enrollment":322},{"nctId":"NCT03943004","phase":"PHASE1","title":"Trial of DFP-14927 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-09-30","conditions":"Solid Tumor, Cancer","enrollment":30},{"nctId":"NCT04066881","phase":"PHASE2","title":"A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2020-12-15","conditions":"HIV Infections","enrollment":1512},{"nctId":"NCT05300035","phase":"PHASE2","title":"Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-11","conditions":"HIV/AIDS and Infections","enrollment":69},{"nctId":"NCT06150014","phase":"PHASE1, PHASE2","title":"A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-07","conditions":"Chronic Hepatitis b","enrollment":88},{"nctId":"NCT06609941","phase":"NA","title":"Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma","status":"RECRUITING","sponsor":"Foundation University Islamabad","startDate":"2024-06-18","conditions":"Bronchial Asthma","enrollment":32},{"nctId":"NCT02484391","phase":"PHASE1","title":"CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-09","conditions":"Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT01998035","phase":"PHASE1, PHASE2","title":"Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies","status":"TERMINATED","sponsor":"Columbia University","startDate":"2013-11","conditions":"Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma","enrollment":58},{"nctId":"NCT04808791","phase":"PHASE2","title":"iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"COMPLETED","sponsor":"AHS Cancer Control Alberta","startDate":"2021-10-27","conditions":"Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma","enrollment":7},{"nctId":"NCT06434467","phase":"PHASE3","title":"The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-05","conditions":"T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma","enrollment":83},{"nctId":"NCT06313255","phase":"","title":"A Retrospective Observational Study on the Effects of Probiotics on HBsAg Clearance","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-05-09","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT01621854","phase":"PHASE1","title":"NUC-1031 in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-10","conditions":"Cancer","enrollment":68},{"nctId":"NCT06196632","phase":"","title":"Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-01-06","conditions":"Hepatitis B, Chronic","enrollment":1000},{"nctId":"NCT06234072","phase":"PHASE2","title":"Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen University General Hospital","startDate":"2024-02","conditions":"Pancreatic Cancer","enrollment":120},{"nctId":"NCT05112484","phase":"","title":"Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2024-06","conditions":"Multiple Sclerosis","enrollment":600},{"nctId":"NCT00089024","phase":"PHASE2","title":"Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-02-25","conditions":"Pancreatic Cancer","enrollment":29},{"nctId":"NCT06039202","phase":"PHASE2","title":"Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Holy Stone Healthcare Co., Ltd","startDate":"2024-01","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":17},{"nctId":"NCT04988035","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-03","conditions":"COVID-19","enrollment":201},{"nctId":"NCT04583969","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-23","conditions":"COVID-19","enrollment":527},{"nctId":"NCT04583956","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-23","conditions":"COVID-19","enrollment":214},{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":"Hepatitis B","enrollment":400},{"nctId":"NCT05833919","phase":"PHASE2","title":"Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2018-07-30","conditions":"Metastatic Breast Cancer","enrollment":122},{"nctId":"NCT00005585","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-04","conditions":"Leukemia","enrollment":838},{"nctId":"NCT03681132","phase":"PHASE4","title":"The Norwegian Nucleoside Analogue Stop Study","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2018-09-20","conditions":"Hepatitis B, Chronic","enrollment":127},{"nctId":"NCT05733000","phase":"PHASE2","title":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-03-08","conditions":"Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":94},{"nctId":"NCT05376124","phase":"","title":"Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-01-01","conditions":"Hepatitis B, Chronic, Virus Diseases","enrollment":110},{"nctId":"NCT02924389","phase":"PHASE4","title":"Dolutegravir in Reservoirs","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"HIV","enrollment":22},{"nctId":"NCT05494528","phase":"NA","title":"Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-05-04","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT04851834","phase":"PHASE1, PHASE2","title":"NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma","status":"TERMINATED","sponsor":"Xennials Therapeutics Australia Pty Ltd","startDate":"2021-08-25","conditions":"Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma","enrollment":12},{"nctId":"NCT03736265","phase":"NA","title":"Carvedilol for Prevention of Esophageal Varices Progression","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2017-10-09","conditions":"Cirrhosis, Liver, Portal Hypertension","enrollment":240},{"nctId":"NCT05298332","phase":"PHASE1","title":"Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects","status":"TERMINATED","sponsor":"Antios Therapeutics, Inc","startDate":"2022-03-29","conditions":"Chronic Hepatitis b","enrollment":37},{"nctId":"NCT03616574","phase":"PHASE1","title":"First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Holy Stone Healthcare Co., Ltd","startDate":"2019-04-09","conditions":"Advanced or Metastatic Solid Tumors, Advanced or Metastatic Colorectal Cancer (mCRC)","enrollment":37},{"nctId":"NCT05466565","phase":"","title":"Antiviral Therapy for Patients With Liver Cancer After Surgery","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2021-12-01","conditions":"Hepatocellular Carcinoma","enrollment":360},{"nctId":"NCT04640168","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 4 (ACTT-4)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-02","conditions":"COVID-19","enrollment":1010},{"nctId":"NCT05426798","phase":"PHASE1","title":"Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-04-29","conditions":"Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":73},{"nctId":"NCT05416008","phase":"","title":"The Relationship Between Long-term Oral Anti Hepatitis B Nucleoside Analogs and Hepatic Steatosis","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2021-07-01","conditions":"Hepatic Steatosis","enrollment":150},{"nctId":"NCT04551261","phase":"PHASE1","title":"GLS4/RTV and TAF Drug-drug Interaction","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-01-10","conditions":"Chronic Hepatitis B","enrollment":28},{"nctId":"NCT05317260","phase":"","title":"Steatohepatitis in Chronic Hepatitis B","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2002-01-01","conditions":"Fatty Liver, Chronic Hepatitis b","enrollment":408},{"nctId":"NCT04492475","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 3 (ACTT-3)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-05","conditions":"COVID-19","enrollment":969},{"nctId":"NCT04280705","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial (ACTT)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-21","conditions":"COVID-19","enrollment":1062},{"nctId":"NCT04401579","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 2 (ACTT-2)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-05-08","conditions":"COVID-19","enrollment":1033},{"nctId":"NCT04965870","phase":"","title":"A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece","status":"COMPLETED","sponsor":"Hellenic Study Group of Psychoneuroimmunology in Cancer","startDate":"2021-06-30","conditions":"Metastatic Colorectal Cancer","enrollment":200},{"nctId":"NCT04302896","phase":"EARLY_PHASE1","title":"Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs","status":"COMPLETED","sponsor":"Rhonda Brand","startDate":"2020-08-31","conditions":"Medication Adherence, HIV","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2624,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Nucleoside Analogs","genericName":"Nucleoside Analogs","companyName":"Third Affiliated Hospital, Sun Yat-Sen University","companyId":"third-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nucleoside analogs are synthetic molecules that mimic natural nucleosides and inhibit viral or cancer cell replication by interfering with nucleic acid synthesis. Used for Viral infections (HIV, hepatitis B, herpes simplex virus, cytomegalovirus), Certain hematologic and solid malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}